License obtained from Kaketsuken is worldwide and exclusive except for Japan.
Baxter International received a worldwide license to Kaketsuken’s drug candidate for the treatment of thrombotic thrombocytopenic purpura (TTP).
Baxter now has the right to exclusively develop, manufacture, and market the recombinant protein ADAMTS13 in all markets except Japan. In this country, Baxter has a coexclusive license for commercialization.
The development of recombinant ADAMTS13, a bio-engineered version of a naturally occurring enzyme that plays a critical role in blood coagulation, will strengthen Baxter’s preclinical pipeline for specialty therapeutics targeting rare diseases, says a Baxter official.
In addition to an upfront payment upon signing the agreement, Baxter will pay Kaketsuken milestone payments upon IND filing, initiation of Phase II and Phase III trials, BLA filings, and FDA approval.